Skip to main content
SpringerLink
Log in

The vasodilatory beta-blockers

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Although well established in treating hypertension and cardiovascular (CV) disease, clinical trial data suggest that β-blockers (eg, atenolol) may be less effective than other antihypertensive classes in reducing stroke and CV mortality despite similar blood pressure (BP) reductions. One possible explanation is that atenolol is less effective in reducing central aortic pressure. Newer vasodilating β-blockers may prove more effective in reducing central pressure and cardiovascular events. Carvedilol and labetalol appear to cause vasodilation through α 1-receptor blockade; nebivolol induces endothelium-dependent vasodilation by stimulating nitric oxide bioactivity. Their favorable hemodynamic profile includes reduction of peripheral vascular resistance (PVR) while maintaining or improving cardiac output (CO), stroke volume, and left ventricular function, whereas nonvasodilating β-blockers tend to raise PVR and reduce CO and left ventricular function. Compared with conventional β-blockers, vasodilating β-blockers have beneficial hemodynamic effects including decreased pressure wave reflection from the periphery, leading to decreases in central aortic blood pressure. Larger trials are needed to determine whether reduced central pressure will translate into improved CV outcomes compared with nonvasodilating β-blockers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  2. Prichard BN, Cruickshank JM, Graham BR: Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 2001, 10:366–386.

    Article  PubMed  CAS  Google Scholar 

  3. Lindholm LH, Carlberg B, Samuelsson O: Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545–1553.

    Article  PubMed  CAS  Google Scholar 

  4. Dahlöf B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895–906.

    Article  PubMed  CAS  Google Scholar 

  5. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (partial update of NICE clinicallguideline 18). NICE clinical guideline 34. Available at: http://www.nice.org.uk/guidance/CG34/niceguidance/pdf/English. Accessed February 21, 2007.

  6. Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: is it a wise choice? Lancet 2004, 364:1684–1689.

    Article  PubMed  CAS  Google Scholar 

  7. Khan N, McAlister FA: Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737–1742.

    PubMed  Google Scholar 

  8. Khan NA, McAlister FA, Rabkin SW, et al.: The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II—therapy. Can J Cardiol 2006, 22:583–593.

    PubMed  CAS  Google Scholar 

  9. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213–1225.

    Article  PubMed  CAS  Google Scholar 

  10. Wilkinson IB, McEniery CM, Cockcorft JR: Atenolol and cardiovascular risk: an issue close to the heart [editorial]. Lancet 2006, 367:627–628.

    Article  PubMed  Google Scholar 

  11. Danchin N, Benetos A, Lopez-Sublet M, et al.: Aortic pulse pressure is related to the presence and extent of coronary artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 2004, 17:129–133.

    Article  PubMed  Google Scholar 

  12. Chirinos JA, Zambrano JP, Chakko S, et al.: Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005, 45:980–985.

    Article  PubMed  CAS  Google Scholar 

  13. Dhakam Z, McEniery CM, Yasmin, et al.: Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006, 19:214–219.

    Article  PubMed  CAS  Google Scholar 

  14. Toda N: Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003, 100:215–234.

    Article  PubMed  CAS  Google Scholar 

  15. Veverka A, Nuzum DS, Jolly JL: Nebivolol: a third-generation β-adrenergic blocker. Ann Pharmacother 2006, 40:1353–1360.

    Article  PubMed  CAS  Google Scholar 

  16. Zanchetti A: Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press 2004, 13(Suppl 1):18–33.

    Google Scholar 

  17. Christensen KL, Mulvany MJ: Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens 2001, 19:1001–1006.

    Article  PubMed  CAS  Google Scholar 

  18. Rizzoni D, Porteri E, Boari GE, et al.: Prognostic significance of small-artery structure in hypertension. Circulation 2003, 108:2230–2235.

    Article  PubMed  Google Scholar 

  19. Buus NH, Bøttcher M, Jørgensen CG, et al.: Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or β-blockade in patients with essential hypertension. Hypertension 2004, 44:465–470.

    Article  PubMed  CAS  Google Scholar 

  20. Nichols WW: Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005, 18:3S–10S.

    Article  PubMed  Google Scholar 

  21. Dunn CJ, Lea AP, Wagstaff AJ: Carvedilol. A reappraisal of its pharm acological properties and therapeutic use in cardiovascular disorders. Drugs 1997, 54:161–185.

    PubMed  CAS  Google Scholar 

  22. Afonso RA, Patarrao RS, Macedo MP, Carmo MM: Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens 2006, 19:419–425.

    Article  PubMed  CAS  Google Scholar 

  23. Yoshioka T, Iwamoto N, Tsukahara F, et al.: Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells. Br J Pharmacol 2000, 129:1530–1535.

    Article  PubMed  CAS  Google Scholar 

  24. Wendt T, van der Does R, Schrader R, et al.: Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol. J Cardiovasc Pharmacol 1987, 10(Suppl 11):S147–S150.

    Article  PubMed  Google Scholar 

  25. Morgan T, Snowden R, Butcher L: Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol 1987, 10(Suppl 11):S124–S129.

    PubMed  Google Scholar 

  26. Moser M, Frishman W: Results of therapy with carvedilol, a β-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 1998, 11:15S–22S.

    Article  PubMed  CAS  Google Scholar 

  27. Kanto JH: Current status of labetalol, the first alpha-and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol 1985, 23:617–628.

    PubMed  CAS  Google Scholar 

  28. Labetalol Hydrochloride Tablets USP [package insert]. Corona, CA: Watson Laboratories, Inc.; 2000.

  29. Opie LH: Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina. Cardiovasc Drugs Ther 1988, 2:369–376.

    Article  PubMed  CAS  Google Scholar 

  30. Novo S, Abrignani MG, Sapienza ND, et al.: Partial regression of vascular structural alterations in hypertensive patients treated with alpha-beta-blocker, labetalol. Int Angiol 1992, 11:137–141.

    PubMed  CAS  Google Scholar 

  31. Bristow MR, Nelson P, Minobe W, Johnson C: Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium [Abstract P-121]. Am J Hypertens 2005, 18(Pt 2):51A–52A.

    Article  Google Scholar 

  32. Pedersen ME, Cockcroft JR: The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 2006, 8:279–286.

    Article  PubMed  CAS  Google Scholar 

  33. Cockcroft JR, Chowienczyk PJ, Brett SE, et al.: Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995, 274:1067–1071.

    PubMed  CAS  Google Scholar 

  34. Dawes M, Brett SE, Chowienczyk PJ, et al.: The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999, 48:460–463.

    Article  PubMed  CAS  Google Scholar 

  35. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001, 104:511–514.

    PubMed  CAS  Google Scholar 

  36. Schmitt M, Avolio A, Qasem A, et al.: Basal NO locally modulates human iliac artery function in vivo. Hypertension 2005, 46:227–231.

    Article  PubMed  CAS  Google Scholar 

  37. Mason RP, Kubant R, Jacob RF, et al.: Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 2006, 48:862–869.

    Article  PubMed  CAS  Google Scholar 

  38. McEniery CM, Schmitt M, Qasem A, et al.: Nebivolol increases arterial distensibility in vivo. Hypertension 2004, 44:305–310.

    Article  PubMed  CAS  Google Scholar 

  39. Kamp O, Sieswerda GT, Visser CA: Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003, 92:344–348.

    Article  PubMed  CAS  Google Scholar 

  40. Galderisi M, Cicala S, D’Errico A, et al.: Nebirolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens 2004, 22:2201–2208.

    Article  PubMed  CAS  Google Scholar 

  41. Kouoh F, Gressier B, Dine T, et al.: In vitro and exvivo antioxidant activities of labetalol on rabbit neutrophil respiratory burst. Adv Ther 2004, 21:178–185.

    PubMed  CAS  Google Scholar 

  42. Jaboureck-Bouttier R, Gressier B, Dine T, et al.: Effects of two antihypertensive agents, labetalol and metoprolol, on the production of reactive oxygen species by normal polymorphonuclear leukocytes in vitro. Hypertens Pregnancy 1999, 18:239–247.

    PubMed  CAS  Google Scholar 

  43. Saijonmaa O, Metsarinne K, Fyhrquist F: Carredilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press 1997, 6:24–28.

    Article  PubMed  CAS  Google Scholar 

  44. Oelze M, Daiber A, Brandes RP, et al.: Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006, 48:677–684.

    Article  PubMed  CAS  Google Scholar 

  45. Mason RP, Kalinowski L, Jacob RF, et al.: Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of Black Americans. Circulation 2005, 112:3795–3801.

    Article  PubMed  CAS  Google Scholar 

  46. Celik T, Iyisoy A, Kursaklioglu H, et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006, 24:591–596.

    Article  PubMed  CAS  Google Scholar 

  47. Fratta-Pasini A, Garbin U, Nava MC, et al.: Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005, 23:589–596.

    Article  PubMed  Google Scholar 

  48. Kuroedov A, Cosentino F, Luscher TF: Pharmacological mechanisms of clinically favorable properties of a selective β1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004, 22:155–168.

    Article  PubMed  CAS  Google Scholar 

  49. Sung C-P, Arleth AJ, Ohlstein EH: Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993, 21:221–227.

    Article  PubMed  CAS  Google Scholar 

  50. Goa KL, Benfield P, Sorkin EM: Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 1989, 37:583–627.

    PubMed  CAS  Google Scholar 

  51. Abernethy DR, Bartos P, Plachetka JR: Labetalol in the treatment of hypertension in elderly and younger patients. J Clin Pharmacol 1987, 27:902–906.

    PubMed  CAS  Google Scholar 

  52. Flamenbaum W, Weber MA, McMahon FG, et al.: Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens 1985, 1:56–69.

    PubMed  CAS  Google Scholar 

  53. von Fallois J, Faulhaber HD: Nebivolol, a beta blocker of the third generation: the current treatment of arterial hypertension: results of a multi-center observational study. Schweiz Rundsch Med Prax 2001, 90:435–441.

    Google Scholar 

  54. Van Nueten L, Dupont AG, Vertommen C, et al.: A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997, 11:139–144.

    Article  PubMed  Google Scholar 

  55. Sarafidis PA, Bakris GL: Do the metabolic effects of β-blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich) 2006, 8:351–356.

    Article  CAS  Google Scholar 

  56. Ambrosioni E, Borghi C: Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension: a meta-analysis. High blood Press Cardiovasc Prev 2005, 12:27–35.

    Article  Google Scholar 

  57. Saunders E, Curry C, Hinds J, et al.: Labetalol compared with propranolol in the treatment of black hypertensive patients. J Clin Hypertens 1987, 3:294–302.

    PubMed  CAS  Google Scholar 

  58. Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201–207.

    Article  PubMed  CAS  Google Scholar 

  59. Jacob S, Rett K, Wicklmayr M, et al.: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996, 14:489–494.

    Article  PubMed  CAS  Google Scholar 

  60. Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997, 126:955–959.

    PubMed  CAS  Google Scholar 

  61. Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 2004, 292:2227–2236.

    Article  PubMed  CAS  Google Scholar 

  62. Poirier L, Cléroux J, Nadeau A, Lacourcière Y: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001, 19:1429–1435.

    Article  PubMed  CAS  Google Scholar 

  63. Pesant Y, Marc-Aurèle J, Bielmann P, et al.: Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther 1999, 6:137–147.

    Article  PubMed  CAS  Google Scholar 

  64. Rizos E, Bairaktari E, Kostoula A, et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003, 8:127–134.

    Article  PubMed  CAS  Google Scholar 

  65. Fogari R, Zoppi A, Lazzari P, et al.: Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997, 11:753–757.

    Article  PubMed  CAS  Google Scholar 

  66. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-wintricular dysfunction: the CARPRICORN randomised trial. Lancet 2001, 357:1385–1390.

    Article  PubMed  CAS  Google Scholar 

  67. Otterstad JE, Ford I: The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002, 4:501–506.

    Article  PubMed  CAS  Google Scholar 

  68. Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  69. Flather MD, Shibata MC, Coats AJ, et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215–225.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

    John R. Cockcroft MD, FRCP

Authors
  1. Michala E. Pedersen DPhil, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R. Cockcroft MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John R. Cockcroft MD, FRCP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedersen, M.E., Cockcroft, J.R. The vasodilatory beta-blockers. Current Science Inc 9, 269–277 (2007). https://doi.org/10.1007/s11906-007-0050-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0050-2

Keywords

Search

Navigation